ANNX Annexon

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Biosciences to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

  • Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 3:00 p.m. ET in Boston, MA; and,
  • Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 8:00 a.m. ET in New York, NY.



Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire

LifeSci Advisors

Media Contact:

Beth Keshishian

917-912-7195



EN
27/08/2025

Underlying

ANNXAnnexon

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Annexon

 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Biosciences to Participate in Upcoming September Investor Conf...

Annexon Biosciences to Participate in Upcoming September Investor Conferences BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 3...

3h / 24m 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing ...

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq L...

August 18, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progr...

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Ki...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Selected by EMA to Participate in Product Development Coordina...

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRI...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER I...

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation Topline Pivotal Phase 3 Data Expected in the Second Half of 2026 Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry ...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch